Publications by authors named "Samara T Pacheco"
Article Synopsis
- Bevacizumab, a targeted cancer therapy, can cause severe complications such as thrombotic microangiopathy (TMA), which is linked to complement dysregulation, though there is limited literature on treating it with eculizumab.
- A case study of a female patient with metastatic breast cancer showed that after experiencing acute kidney injury and being diagnosed with TMA related to bevacizumab, her condition improved significantly after receiving eculizumab following the discontinuation of bevacizumab.
- The findings suggest that eculizumab may help reverse TMA in bevacizumab-treated patients, highlighting the need for further clinical trials to assess its safety and effectiveness in such cases.
Background: Prognostic and predictive markers in metastatic pheochromocytoma and paraganglioma (mPPGL) are unknown. We aimed to evaluate epidemiology of mPPGL, and prognostic factors of overall survival (OS) and predictive markers of treatment duration with first-line chemotherapy (TD1L).
Patients And Methods: Retrospective multicentre study of adult patients with mPPGL treated in Latin American centres between 1982 and 2021.